Skip to main content

Advertisement

SpringerLink
Log in

Top Peritoneal Surface Malignancy Articles from 2022 to Inform your Cancer Practice

  • Peritoneal Surface Malignancy
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

Over the last few decades, the role of cytoreductive surgery (CRS) with or without regional-based peritoneal therapies such as hyperthermic intraperitoneal chemotherapy (HIPEC) has evolved in the management of patients with peritoneal surface malignances (PSMs). Despite the benefit of CRS in improving oncologic outcomes, significant challenges remain in the treatment of patients with advanced PSMs, and the role of HIPEC continues to be questioned. Additionally, while there has been improvement in perioperative outcomes, long-term survival remains poor. As a result, there is much need to improve our understanding of the processes that drive tumor biology, thereby improving patient selection for various treatment approaches. Additionally, newer therapies are needed for patients who remain poor surgical candidates and who progress on systemic therapy. This article highlights recently published studies that we consider impactful in the care of patients with PSMs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carcinomatosis from non-gynecologic malignancies. Cancer. 2000;88(2):358–63. https://doi.org/10.1002/(SICI)1097-0142(20000115)88:2%3c358::AID-CNCR16%3e3.0.CO;2-O.

    Article  CAS  PubMed  Google Scholar 

  2. Kusamura S, Barretta F, Yonemura Y, et al. The Role of Hyperthermic Intraperitoneal Chemotherapy in Pseudomyxoma Peritonei After Cytoreductive Surgery. JAMA Surg. 2021;156(3):e206363. https://doi.org/10.1001/jamasurg.2020.6363.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Lundy ME, Moaven O, Perry KC, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Cancer with Peritoneal Dissemination: 30 Years of Experience at a Single Institution. J Am Coll Surg. 2022;234(4):546–56. https://doi.org/10.1097/XCS.0000000000000091.

    Article  PubMed  Google Scholar 

  4. Tseng J, Bryan DS, Poli E, Sharma M, Polite BN, Turaga KK. Under-representation of peritoneal metastases in published clinical trials of metastatic colorectal cancer. Lancet Oncol. 2017;18(6):711–2. https://doi.org/10.1016/S1470-2045(17)30336-4.

    Article  PubMed  Google Scholar 

  5. Guner A, Yildirim R. Surgical management of metastatic gastric cancer: moving beyond the guidelines. Transl Gastroenterol Hepatol. 2019;4:58. https://doi.org/10.21037/tgh.2019.08.03.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ikoma N, Chen HC, Wang X, et al. Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Ann Surg Oncol. 2017;24(9):2679–87. https://doi.org/10.1245/s10434-017-5838-y.

    Article  PubMed  Google Scholar 

  7. Spolverato G, Ejaz A, Kim Y, et al. Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional Analysis. J Am Coll Surg. 2014;219(4):664–75. https://doi.org/10.1016/j.jamcollsurg.2014.03.062.

    Article  PubMed  Google Scholar 

  8. Agnes A, Biondi A, Persiani R, et al. Development of the PERI-Gastric (PEritoneal Recurrence Index) and PERI-Gram (Peritoneal Recurrence Index NomoGRAM) for predicting the risk of metachronous peritoneal carcinomatosis after gastrectomy with curative intent for gastric cancer. Gastric Cancer. 2022;25(3):629–39. https://doi.org/10.1007/s10120-021-01268-4.

    Article  CAS  PubMed  Google Scholar 

  9. Agnes A, Biondi A, Laurino A, et al. A detailed analysis of the recurrence timing and pattern after curative surgery in patients undergoing neoadjuvant therapy or upfront surgery for gastric cancer. J Surg Oncol. 2020;122(2):293–305. https://doi.org/10.1002/jso.25959.

    Article  PubMed  Google Scholar 

  10. Mariette C, Carneiro F, Grabsch HI, van der Post RS, Allum W, de Manzoni G. Consensus on the pathological definition and classification of poorly cohesive gastric carcinoma. Gastric Cancer. 2019;22(1):1–9. https://doi.org/10.1007/s10120-018-0868-0.

    Article  CAS  PubMed  Google Scholar 

  11. Charalampakis N, Nogueras González GM, Elimova E, et al. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology. 2016;90(5):239–47. https://doi.org/10.1159/000443506.

    Article  CAS  PubMed  Google Scholar 

  12. Chen QY, Zhong Q, Zhou JF, et al. Conditional survival and recurrence of remnant gastric cancer after surgical resection: A multi-institutional study. Cancer Sci. 2020;111(2):502–12. https://doi.org/10.1111/cas.14231.

    Article  CAS  PubMed  Google Scholar 

  13. Yonemura Y, Sugiyama K, Fujimura T, et al. A new surgical technique (left upper abdominal evisceration) for advanced carcinoma of the gastric stump. Hepatogastroenterology. 1994;41(2):130–3.

    CAS  PubMed  Google Scholar 

  14. Ikoma N, Blum M, Chiang YJ, et al. Yield of Staging Laparoscopy and Lavage Cytology for Radiologically Occult Peritoneal Carcinomatosis of Gastric Cancer. Ann Surg Oncol. 2016;23(13):4332–7. https://doi.org/10.1245/s10434-016-5409-7.

    Article  PubMed  Google Scholar 

  15. Takebayashi K, Murata S, Yamamoto H, et al. Surgery-Induced Peritoneal Cancer Cells in Patients Who Have Undergone Curative Gastrectomy for Gastric Cancer. Ann Surg Oncol. 2014;21(6):1991–7. https://doi.org/10.1245/s10434-014-3525-9.

    Article  PubMed  Google Scholar 

  16. Lee JH, Son SY, Lee CM, Ahn SH, Park DJ, Kim HH. Factors predicting peritoneal recurrence in advanced gastric cancer: implication for adjuvant intraperitoneal chemotherapy. Gastric Cancer. 2014;17(3):529–36. https://doi.org/10.1007/s10120-013-0306-2.

    Article  CAS  PubMed  Google Scholar 

  17. Seyfried F, von Rahden BH, Miras AD, et al. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin – a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer. 2015;15(1):73. https://doi.org/10.1186/s12885-015-1081-8.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Glehen O, Passot G, Villeneuve L, et al. GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer. 2014;14(1):183. https://doi.org/10.1186/1471-2407-14-183.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Di Giorgio A, Gerardi C, Abatini C, et al. Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery for gastric carcinoma at high risk of peritoneal carcinomatosis: short and long-term outcomes (GOETH STUDY)—a collaborative randomized controlled trial by ACOI, FONDAZIONE AIOM, SIC, SICE, and SICO. Trials. 2022;23(1):969. https://doi.org/10.1186/s13063-022-06880-y.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Quere P, Facy O, Manfredi S, et al. Epidemiology, Management, and Survival of Peritoneal Carcinomatosis from Colorectal Cancer. Diseases of the Colon & Rectum. 2015;58(8):743–52. https://doi.org/10.1097/dcr.0000000000000412.

    Article  CAS  Google Scholar 

  21. Franko J, Shi Q, Meyers JP, et al. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol. 2016;17(12):1709–19. https://doi.org/10.1016/s1470-2045(16)30500-9.

    Article  PubMed  Google Scholar 

  22. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. British Journal of Surgery. 2002;89(12):1545–50. https://doi.org/10.1046/j.1365-2168.2002.02274.x.

    Article  CAS  PubMed  Google Scholar 

  23. Solsky I, Moaven O, Valenzuela CD, et al. Survival Outcomes of Optimally Treated Colorectal Metastases: The Importance of R0 Status in Surgical Treatment of Hepatic and Peritoneal Surface Disease. Ann Surg Oncol. 2023;30(7):4264–73. https://doi.org/10.1245/s10434-023-13174-3.

    Article  PubMed  Google Scholar 

  24. Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS Open. 2019;3(5):585–94. https://doi.org/10.1002/bjs5.50179.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Bos JL, Fearon ER, Hamilton SR, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature. 1987;327(6120):293–7. https://doi.org/10.1038/327293a0.

    Article  CAS  PubMed  Google Scholar 

  26. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. RAF/RAS oncogenes and mismatch-repair status. Nature. 2002;418(6901):934–934. https://doi.org/10.1038/418934a.

    Article  CAS  PubMed  Google Scholar 

  27. Tonello M, Baratti D, Sammartino P, et al. Microsatellite and RAS/RAF Mutational Status as Prognostic Factors in Colorectal Peritoneal Metastases Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Ann Surg Oncol. 2022;29(6):3405–17. https://doi.org/10.1245/s10434-021-11045-3.

    Article  PubMed  Google Scholar 

  28. Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219–26. https://doi.org/10.1200/JCO.2009.27.1825.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Jover R, Zapater P, Castells A, et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer. 2009;45(3):365–73. https://doi.org/10.1016/j.ejca.2008.07.016.

    Article  CAS  PubMed  Google Scholar 

  30. Ozer M, Vegivinti CTR, Syed M, et al. Neoadjuvant Immunotherapy for Patients with dMMR/MSI-High Gastrointestinal Cancers: A Changing Paradigm. Cancers (Basel). 2023;15(15):3833. https://doi.org/10.3390/cancers15153833.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Case A, Prosser S, Peters CJ, Adams R, Gwynne S. Pressurised intraperitoneal aerosolised chemotherapy (PIPAC) for gastric cancer with peritoneal metastases: A systematic review by the PIPAC UK collaborative. Crit Rev Oncol Hematol. 2022;180. doi: https://doi.org/10.1016/j.critrevonc.2022.103846

  32. Di Giorgio A, Macrì A, Ferracci F, et al. 10 Years of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): A Systematic Review and Meta-Analysis. Cancers (Basel). 2023;15(4):1125. https://doi.org/10.3390/cancers15041125.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Sgarbura O, Hübner M, Alyami M, et al. Oxaliplatin use in pressurized intraperitoneal aerosol chemotherapy (PIPAC) is safe and effective: A multicenter study. European Journal of Surgical Oncology. 2019;45(12):2386–91. https://doi.org/10.1016/j.ejso.2019.05.007.

    Article  PubMed  Google Scholar 

  34. Rovers KP, Wassenaar ECE, Lurvink RJ, et al. Pressurized Intraperitoneal Aerosol Chemotherapy (Oxaliplatin) for Unresectable Colorectal Peritoneal Metastases: A Multicenter, Single-Arm, Phase II Trial (CRC-PIPAC). Ann Surg Oncol. 2021;28(9):5311–26. https://doi.org/10.1245/s10434-020-09558-4.

    Article  PubMed  Google Scholar 

  35. Nowacki M, Alyami M, Villeneuve L, et al. Multicenter comprehensive methodological and technical analysis of 832 pressurized intraperitoneal aerosol chemotherapy (PIPAC) interventions performed in 349 patients for peritoneal carcinomatosis treatment: An international survey study. European Journal of Surgical Oncology. 2018;44(7):991–6. https://doi.org/10.1016/j.ejso.2018.02.014.

    Article  PubMed  Google Scholar 

  36. Raoof M, Whelan RL, Sullivan KM, et al. Safety and Efficacy of Oxaliplatin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Colorectal and Appendiceal Cancer with Peritoneal Metastases: Results of a Multicenter Phase I Trial in the USA. Ann Surg Oncol. 2023;30(12):7814–24. https://doi.org/10.1245/s10434-023-13941-2.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 2013;381(9863). doi:https://doi.org/10.1016/S0140-6736(12)61900-X

  38. Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer. New England Journal of Medicine. 2015;372(20). doi:https://doi.org/10.1056/nejmoa1414325

  39. Kim G, Tan HL, Sundar R, et al. PIPAC-OX: A phase I study of oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy in patients with peritoneal metastases. Clinical Cancer Research. 2021;27(7). doi: https://doi.org/10.1158/1078-0432.CCR-20-2152

  40. Hübner M, Alyami M, Villeneuve L, et al. Consensus guidelines for pressurized intraperitoneal aerosol chemotherapy: Technical aspects and treatment protocols: PIPAC practice guidelines. European Journal of Surgical Oncology. 2022;48(4). doi: https://doi.org/10.1016/j.ejso.2021.10.028

  41. Sugarbaker PH, Bijelic L, Chang D, Yoo D. Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. J Surg Oncol. 2010;102(6):576–81. https://doi.org/10.1002/jso.21679.

    Article  PubMed  Google Scholar 

  42. Milovanov V, Sardi A, Ledakis P, et al. Systemic chemotherapy (SC) before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) in patients with peritoneal mucinous carcinomatosis of appendiceal origin (PMCA). European Journal of Surgical Oncology. 2015;41(5):707–12. https://doi.org/10.1016/j.ejso.2015.01.005.

    Article  CAS  PubMed  Google Scholar 

  43. Mangieri CW, Moaven O, Valenzuela CD, et al. Utility of Neoadjuvant Chemotherapy for Peritoneal Carcinomatosis Secondary to High-Grade Appendiceal Neoplasms for Patients Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy. Ann Surg Oncol. 2022;29(4):2641–8. https://doi.org/10.1245/s10434-021-11153-0.

    Article  PubMed  Google Scholar 

  44. Grotz TE, Overman MJ, Eng C, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. Ann Surg Oncol. 2017;24(9). doi:https://doi.org/10.1245/s10434-017-5938-8

  45. Morgan RB, Yan A, Dhiman A, et al. Survival in Total Preoperative vs. Perioperative Chemotherapy for Patients with Metastatic High-Grade Appendiceal Adenocarcinoma Undergoing CRS/HIPEC. Journal of Gastrointestinal Surgery. 2022;26(12):2591–4. https://doi.org/10.1007/s11605-022-05423-9.

    Article  PubMed  Google Scholar 

  46. Hanna DN, Macfie R, Ghani MO, et al. Association of Systemic Chemotherapy Approaches With Outcomes in Appendiceal Peritoneal Metastases. Journal of Surgical Research. 2023;284:94–100. https://doi.org/10.1016/j.jss.2022.10.085.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, Division of General Surgery, University of Washington/Fred Hutch Cancer Center, Seattle, WA, USA

    Harveshp Mogal MD, MS, FACS

  2. Department of Surgery, Division of Surgical Oncology, Atrium Health Wake Forest Baptist, Winston Salem, NC, USA

    Perry Shen MD, FACS

Authors
  1. Harveshp Mogal MD, MS, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Perry Shen MD, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harveshp Mogal MD, MS, FACS.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mogal, H., Shen, P. Top Peritoneal Surface Malignancy Articles from 2022 to Inform your Cancer Practice. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15304-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1245/s10434-024-15304-x

Search

Navigation